TCTC Holdings’s Biogen BIIB Stock Holding History

TCTC Holdings’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-600	Closed	-$106K	–	256
2025 Q4	$106K	Hold	600	–	–	﹤0.01%	267
2025 Q3	$84K	Sell	600 -300	-33%	-$40.6K	﹤0.01%	283
2025 Q2	$113K	Hold	900	–	–	﹤0.01%	251
2025 Q1	$123K	Hold	900	–	–	﹤0.01%	238
2024 Q4	$138K	Hold	900	–	–	﹤0.01%	232
2024 Q3	$174K	Hold	900	–	–	0.01%	214
2024 Q2	$209K	Hold	900	–	–	0.01%	197
2024 Q1	$194K	Hold	900	–	–	0.01%	191
2023 Q4	$233K	Hold	900	–	–	0.01%	174
2023 Q3	$231K	Hold	900	–	–	0.01%	170
2023 Q2	$256K	Hold	900	–	–	0.01%	169
2023 Q1	$250K	Hold	900	–	–	0.01%	173
2022 Q4	$249K	Sell	900 -500	-36%	-$141K	0.01%	165
2022 Q3	$374K	Hold	1,400	–	–	0.02%	144
2022 Q2	$286K	Hold	1,400	–	–	0.01%	157
2022 Q1	$295K	Hold	1,400	–	–	0.01%	166
2021 Q4	$336K	Hold	1,400	–	–	0.01%	169
2021 Q3	$396K	Hold	1,400	–	–	0.02%	146
2021 Q2	$485K	Buy	+1,400	New	+$424K	0.02%	137

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

TCTC Holdings's BIIB Position: Q1 2026 in Review

TCTC Holdings sold out of Biogen (BIIB) in Q1 2026, closing a stake of 600 shares — an estimated $106K sold.

TCTC Holdings first reported a position in BIIB in Q2 2021 and held it in 19 quarters. The position peaked at $485K in Q2 2021. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

TCTC Holdings reported no remaining Biogen position as of Q1 2026 after selling out during the quarter.
TCTC Holdings sold 600 Biogen shares in Q1 2026, an estimated $106K.
TCTC Holdings first reported a position in Biogen in Q2 2021 and held it in 19 quarters.
TCTC Holdings's Biogen position peaked at $485K in Q2 2021.
1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on TCTC Holdings's 13F filing for Q1 2026, filed 7 May 2026.